[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452882":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":62,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":26,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Jessa Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","Patients allocated to the treatment group will receive scalp cooling combined with thrice weekly PBM sessions during the CTx course and until one month after the end of CTx.",[13,14],"Device: Theradome® LH80 pro","Device: Scalp cooling",{"label":16,"type":17,"description":18,"interventionNames":19},"Control group","ACTIVE_COMPARATOR","Patients allocated to the control group will receive scalp cooling during their CTx course.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Theradome® LH80 pro","The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Scalp cooling","Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.",[16,9],[32],{"name":33,"affiliation":5,"role":34},"Jeroen Mebis, Prof. Dr.","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+32 11 33 72 21","jeroen.mebis@jessazh.be",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Marithé Claes, MSc","+32 11 33 72 39","marithe.claes@uhasselt.be",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Hasselt","Limburg","3500","Belgium","BE",{"type":53,"coordinates":54},"Point",[55,56],5.33781,50.93106,{"lat":56,"lon":55},[59,60],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"name":61,"role":37,"phone":42,"phoneExt":26,"email":43},"Marithé Marithé, MSc",{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100452882","photobiomodulation-therapy-in-the-prevention-and-management-of-chemotherapy-induced-alopecia-100452882",false,"NCT05177289","Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia","Evaluating the Feasibility and Efficacy of Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-induced Alopecia: a Randomized Controlled Trial","HairLight","Inclusion Criteria:\n\n* Diagnosed with gynecological cancer (endometrium, cervix, ovarian or vulva) or breast cancer\n* Receiving chemotherapy ((Carbo)-Taxol)\n* Age ≥ 18 years\n* Able to comply to the study protocol\n* Able to sign written informed consent\n\nExclusion Criteria:\n\n* Metastatic disease\n* Pregnancy\n* Active infection of the scalp\n* Previous diagnosis of a hair loss condition\n* Interruption of chemotherapy for more than two consecutive cycles\n* Medication to stimulate hair growth (e.g., Minoxidil)\n* Severe psychological disorder or dementia.\n* Inability to speak and understand Dutch\n* Substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator\n* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator","FEMALE","18 Years",{"count":75,"type":76},72,"ESTIMATED","INTERVENTIONAL",[79],"NA","This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the prevention and management of chemotherapy-induced alopecia (CIA). Therefore, we hypothesize that PBMT can reduce the severity of CIA in gynecological and breast cancer patients, increasing the patient's QoL.",[82],"Chemotherapy-induced Alopecia",[84],"Photobiomodulation therapy","2023-09-28",{"date":87,"type":88},"2023-09-29","ACTUAL",{"date":90,"type":88},"2022-02-28",{"date":92,"type":76},"2030-01",{"name":5,"class":6},1]